Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2020-09-21 Board/Management Inform…
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargias valberedning föreslår ny styrelseledamot
Board/Management Information Classification · 100% confidence The document is a press release from Cantargia AB announcing a proposal by the nomination committee to appoint a new member to the board of directors. This falls under the category of board or management changes, specifically the announcement of a new board member candidate.
2020-09-21 Swedish
Annual Report 2019
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2019' and contains comprehensive sections including a Director's Report, Financial Statements, Auditor's Report, and Corporate Governance. It covers the full fiscal year of 2019 for Cantargia AB, providing detailed financial performance, business strategy, and operational updates. It meets all criteria for a formal Annual Report. FY 2019
2020-08-24 English
Annual Report 2018
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2018' for Cantargia AB. It contains a comprehensive table of contents, a CEO review, a Directors' report, audited financial statements, and corporate governance information. It meets the criteria for a full annual report as it covers company activity and financial performance for the fiscal year. FY 2018
2020-08-24 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT' (Interim Report) for the period January - June 2020. It contains comprehensive financial data, including income statements, balance sheet items (soliditet, likvida medel), and detailed management commentary on business operations, clinical trials, and market analysis. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2020
2020-08-20 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT' and covers the period 'January - June 2020'. It contains detailed financial statements (Net sales, Operating loss, Loss after tax, etc.) for the second quarter and the first half of the year, along with management commentary, business strategy, and market analysis. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2020
2020-08-20 English
New number of shares and votes in Cantargia
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a short press release dated July 31, 2020, announcing a change in the total number of outstanding shares and votes due to the exercise of warrants by a board member. This directly relates to a change in the company's share capital structure. This fits the definition of 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a dividend notice (DIV) or director's dealing (DIRS), although it involves a director exercising warrants, the primary focus is the resulting change in the total share count.
2020-07-31 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.